Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin Alpha 1 for Sepsis
NCT02883595Phase 4Completed
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2016
- Primary completion
- Sep 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial in sepsis comparing thymosin alpha 1 with Placebo (2 arms). Primary endpoint: Immune function of monocyte (phagocytosis, antigen presenting, apoptosis) at 28 days. Started Mar 2016; status: completed.
02
Drugs
thymosin alpha 1
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT02883595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02883595.